Condition deep-dive · 6 min read

Hidradenitis Suppurativa — supplement adjuncts to dermatology care

Updated 2026-05-13 · Reviewed by SupplementScore editors · No sponsorships

Hidradenitis suppurativa (HS, acne inversa) is a chronic, recurrent, inflammatory skin condition affecting intertriginous areas (axillae, groin, perineum, gluteal cleft, inframammary skin) and characterised by painful nodules, abscesses, sinus tracts, and scarring. The pathology involves follicular occlusion, dysbiotic skin microbiome, and dysregulated innate immunity. Medical care dominates outcomes — topical and systemic antibiotics for flares, anti-androgen options in women, hormonal modulation, biologics (adalimumab, secukinumab, bimekizumab) for moderate-to-severe disease, and surgery for chronic sinus tracts. Supplements have a narrow but real adjunct role: zinc gluconate has the strongest evidence base; vitamin D correction matters; dietary modifications (dairy, brewer's yeast) help a subset.

Read this first. HS is under-recognised and frequently mismanaged as "recurrent boils." Earlier dermatology engagement substantially improves long-term outcomes by preventing tract formation and scarring. Persistent painful nodules in intertriginous areas warrant dermatology assessment — supplements don't substitute for that. Smoking cessation is the single highest-leverage modifiable intervention. Weight loss in users with overweight/obesity is the second.

The supplement adjuncts with reasonable role

Tier 2 evidence · Strongest signal among supplements

Zinc gluconate

90 mg elemental zinc/day in divided doses for active phase, taper to 30–45 mg/day maintenance under dermatology guidance; copper supplementation 1–2 mg/day at maintenance

The Brocard 2007 open-label trial and several subsequent cohort reports support zinc gluconate at 90 mg elemental daily as adjunct therapy. Mechanism involves anti-inflammatory and anti-androgenic effects. High-dose zinc warrants copper co-supplementation to avoid copper deficiency anemia and neutropenia. Coordinate with dermatology.

Tier 2 evidence · Common deficiency in HS

Vitamin D3

Test 25-OH-D and supplement to 30–50 ng/mL; typical maintenance 1,000–2,000 IU/day; often higher correction needed

Vitamin D deficiency is more common in HS populations and is observationally associated with disease severity. Whether supplementation improves disease activity directly remains uncertain, but correction of deficiency is reasonable both for general health and possible adjunct effect.

Tier 3 evidence · For dairy-trigger phenotype

Dairy elimination trial

8-week elimination of dairy products; observe for flare frequency; reintroduce systematically

Case series and patient-reported outcomes suggest a subset of HS users have dairy-trigger flares (proposed mechanism: insulin-like growth factor and IGF-1 effects on follicular keratinocytes). Empirical trial of 8-week elimination is low-risk and informative — keep food and symptom diary, reintroduce systematically.

Tier 3 evidence · Yeast-trigger phenotype

Brewer's yeast / refined sugar elimination trial

Eliminate brewer's yeast / nutritional yeast / beer; reduce refined sugars; 8-week observation

Case series link brewer's yeast exposure to HS flares in some users. Reducing refined sugars and elimination of brewer's yeast is a low-risk empirical trial. Effect varies; consider as one of multiple personalised approaches.

Tier 2 evidence · For metabolic-syndrome co-component

Omega-3 (EPA/DHA)

1–2 g/day EPA+DHA with meals

HS is associated with metabolic syndrome, cardiovascular risk, and chronic inflammation. Omega-3 has anti-inflammatory and cardiovascular benefits independent of skin effect; reasonable as part of overall risk reduction.

What to skip

High-dose biotin "for skin" — interferes with lab assays (troponin, thyroid, hCG) at high doses; no HS evidence.
"Detox" / "cleanse" supplements — no role.
Essential oils as topical treatment — risk of contact dermatitis in already-fragile intertriginous skin.
Vitamin B12 megadoses — case reports link high-dose B12 to acneiform / HS-pattern eruptions; if HS pattern flares on a high-dose B12 product, reassess.
"Hormone balancing" herbs (DIM, calcium d-glucarate, etc.) without endocrinology input — anti-androgen prescription options (spironolactone, oral contraceptives) have real evidence in women with HS; herbal substitutes don't.
High-dose iodine / kelp — exacerbates acneiform conditions in some users.

The dermatology framework that dominates outcomes

Smoking cessation — the single highest-leverage modifiable factor in HS prognosis. Strongly associated with disease severity and progression.
Weight loss in users with overweight/obesity — improves disease activity and reduces frictional triggers.
Topical clindamycin and chlorhexidine washes — first-line for mild disease.
Oral antibiotics — tetracyclines (doxycycline, minocycline) long-term, or rifampicin + clindamycin combination for moderate disease.
Anti-androgens in women — spironolactone, ethinylestradiol-containing OCPs, finasteride in selected cases.
Biologics — adalimumab is FDA-approved for moderate-to-severe HS; secukinumab and bimekizumab have newer approvals or indications. Biologic-eligible users benefit substantially from earlier escalation.
Surgical management — incision and drainage is short-term; deroofing or wide local excision of chronic tracts is curative for affected anatomic areas.
Wound and pain management — pain in HS is chronic and undertreated; pain specialist involvement for severe cases.
Mental health support — HS has substantially elevated depression and suicide risk; psychological support is part of comprehensive care.

Practical quick-start. See dermatology promptly — earlier engagement reduces long-term scarring. Smoking cessation is the highest-leverage intervention. Weight loss if BMI >27. Zinc gluconate 90 mg elemental daily (with copper 1–2 mg) under dermatology guidance for active disease. Test and correct 25-OH-D. Trial 8-week dairy elimination and consider brewer's yeast / refined sugar reduction. Coordinate medical care including biologic candidacy assessment for moderate-severe disease.

What to track

Hurley stage at baseline and follow-up. HiSCR (HS Clinical Response) for biologic candidates. Number of inflammatory nodules, abscesses, draining tracts. Flare frequency. Pain (NRS). Quality of life (DLQI). Smoking status. Weight / BMI. 25-OH-D. Mental health (PHQ-9 screening). Coordinate dermatology, primary care, smoking cessation support, and psychology / pain specialty as needed.